Golden State Wealth Management’s Vaxart VXRT Stock Holding History

Golden State Wealth Management’s Portfolio VXRT Stock Details VXRT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-1	Closed	-$1	–	1646
2024 Q4	$1	Buy	+1	New	+$1	﹤0.01%	1513
2020 Q4	–	Sell	-1,000	Closed	-$7K	–	420
2020 Q3	$7K	Buy	+1,000	New	+$8.91K	﹤0.01%	411
2020 Q2	–	Sell	-1,000	Closed	-$2K	–	906
2020 Q1	$2K	Buy	+1,000	New	+$1.27K	﹤0.01%	881

Other funds holding VXRT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Golden State Wealth Management's VXRT Position: Q1 2025 in Review

Golden State Wealth Management sold out of Vaxart (VXRT) in Q1 2025, closing a stake of 1 share — an estimated $1 sold.

Golden State Wealth Management first reported a position in VXRT in Q1 2020 and held it in 3 quarters. The position peaked at $7K in Q3 2020. 92 funds tracked by Wall St. Rank hold VXRT as of Q1 2025.

Golden State Wealth Management reported no remaining Vaxart position as of Q1 2025 after selling out during the quarter.
Golden State Wealth Management sold 1 Vaxart share in Q1 2025, an estimated $1.
Golden State Wealth Management first reported a position in Vaxart in Q1 2020 and held it in 3 quarters.
Golden State Wealth Management's Vaxart position peaked at $7K in Q3 2020.
92 funds tracked by Wall St. Rank held Vaxart as of Q1 2025.

Based on Golden State Wealth Management's 13F filing for Q1 2025, filed 23 Apr 2025.